Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 43Terminated 6Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Adenoma, Islet Cell 1

Interventions

pembrolizumab 562Specimen Handling 490Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 406Radiotherapy 353Gemcitabine 314Bevacizumab 313Paclitaxel 298Biopsy 290Drug Therapy 283Blood Specimen Collection 248Capecitabine 245Oxaliplatin 241fludarabine 240Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 205Dexamethasone 187Radiosurgery 182Rituximab 159Standard of Care 158Pemetrexed 156Surgical Procedures, Operative 148durvalumab 145atezolizumab 145Leucovorin 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × incomplete Freund's adjuvant × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡